SELLAS Life Sciences Group, Inc. - SLS EV/Sales Multiple

SELLAS Life Sciences Group, Inc. (SLS) - corporate logo

SELLAS Life Sciences is implementing cloud AI and laboratory robotics to analyze clinical data. The company is developing a diversified portfolio of immunotherapeutic vaccines against leukemia and solid tumors. The brand's reputation is built on combating cancer recurrence. This enterprise value-to-revenue chart illustrates the business valuation trend, where 0.00 represents the latest metric level.

SLS SELLAS Life Sciences Group: Company Value to Revenue in the range 11/23/2025 - 11/19/2026

SELLAS Life Sciences Group, Inc. - analytical breakdowns and key metrics (SLS)

Fundamental company valuation:SELLAS Life Sciences Group, Inc.
Flagship merchandise of SELLAS Life Sciences Group

Fundamental risks for SELLAS Life Sciences (SLS) are driven by the volatility of market multiples. Geopolitical barriers in clinical trials directly impact the business's investment attractiveness. This change in enterprise value-to-revenue measures the combined value of assets and debts relative to sales, excluding the impact of leverage. The metric demonstrates the resilience of capitalization to external shocks. An increase in this indicator signals overvaluation, creating the risk of a prolonged correction.

Competitor analysis for SELLAS Life Sciences

Enterprise Value-to-Sales Ratio BeiGene Ltd (ONC)|Halozyme Corp (HALO) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Revolution Medicines Inc (RVMD)|Enterprise Value-to-Revenue Ratio Ascentage Pharma Group|Company Value to Revenue Ratio CGON (CG Oncology Corp)|Enterprise Value-to-Revenue Ratio UroGen Pharma (URGN)|EV/Sales Multiple Bicara Therapeutics (BCAX)|EV/Sales Multiple PSNL (personalis.com)|Business Value to Revenue ERAS|DCTH: Company Value to Revenue|YmAbs - Enterprise Value-to-Revenue Coefficient|aurabiosciences.com (AURA) - Enterprise Value-to-Revenue Ratio|Candel Therapeutics Inc. - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Accuray Inc.|ACTU: Business Value to Revenue|Enterprise Value-to-Revenue Ratio citiusonc.com (CTOR)|Total Company Value-to-Revenue Ratio TuHURA Biosciences|Enterprise Value-to-Revenue Ratio Protara Therapeutics TARA|Fate Therapeutics (FATE) - Enterprise Value-to-Revenue Multiple|WHWK - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple TScan Therapeutics Inc|championsoncology.com (CSBR) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Ratio XBIT|Company Value to Revenue CVM|Company Value to Revenue Ratio OSTX (OS Therapies Incorporated)|EV/Sales Multiple RADX|ARTV: Enterprise Value to Sales Volume|EV/Sales Multiple ANL (Adlai Nortye Ltd)|VERU - Company Value to Revenue|tempesttx.com - EV/Sales Multiple|Business Value to Revenue XLO (xiliotx.com)|RENB: EV/Sales Multiple|Company Value to Revenue Mural Oncology plc|Enterprise Value-to-Revenue Ratio Kairos Pharma Inc|OKUR: Business Value to Revenue|EV/Sales Multiple GDTC|CRIS (Curis) - Business Value to Revenue|Enterprise Value-to-Revenue Ratio apollomicsinc.com APLM|THAR: Company Value to Revenue Ratio|advanbiomed.com - EV/Sales Multiple|Business Value to Revenue GNPX (Genprex, Inc)|Calidi Biotherapeutics Inc. (CLDI) - Enterprise Value-to-Revenue Ratio|Sunshine Biopharma Inc. (SBFM) - EV/Sales Multiple|XBIO (Xenetic Bio) - EV/Sales Multiple|Salarius Pharmaceuticals Inc (SLRX) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple PPBT|EV/Sales Multiple American Oncology Network Inc (AONC)|EV/Sales Multiple BGNE (BeiGene Ltd.)|Enterprise Value-to-Revenue Coefficient CKPT (Checkpoint Therapeutics)|ELEV - Enterprise Value-to-Revenue Ratio|ICAD (iCAD Inc.) - Company Value to Revenue Ratio|Ikena (IKNA) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Notable Labs, Ltd.|Enterprise Value-to-Revenue Ratio viracta.com|MOR: Business Value to Revenue|EV/Sales Multiple NAYA|Ascentage Pharma - Company Value to Revenue Ratio